Evidence corner

STUDIES ORGANIZED BY CATEGORIES

In the evidence corner these studies, instead of being organized by dates, are organized by other categories (drug class, surgery…).
The summaries in this section are presented in a much more reduced way.

  1. UC proctitis

  2. Type of drug

  3. Post operative recurrence in CD

  4. Perianal disease

  5. Paediatric

  6. Fertility, sexuality & paternal outcomes in men with IBD

    1. Prevalence of Sexual Dysfunction in Inflammatory Bowel Disease: Systematic Review and Meta-analysis
    2. Prevalence of Sexual Dysfunction in Inflammatory Bowel Disease: Systematic Review and Meta-analysis
    3. Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-analysis
    4. The Prevalence and Associated Risk Factors of Erectile Dysfunction in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    5. Prevalence and risk factors of sexual dysfunction in patients with inflammatory bowel disease: systematic review and meta-analysis
    6. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases
    7. Men With Inflammatory Bowel Disease: Sexual Function, Fertility, Medication Safety, and Prostate Cancer
    8. Inflammatory Bowel Diseases Were Associated With Risk of Sexual Dysfunction in Both Sexes: A Meta-analysis
    9. Inflammatory Bowel Disease Therapies Adversely Affect Fertility in Men- A Systematic Review and Meta-analysis
  7. Conception, pregnancy, postpartum & lactation

    1. Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation
    2. Thiopurine Metabolite Shunting in Late Pregnancy Increases the Risk of Intrahepatic Cholestasis of Pregnancy in Women With Inflammatory Bowel Disease, and Can be Managed With Split Dosing
    3. Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease
    4. Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis
    5. Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis
    6. Inflammatory bowel disease can reduce ovarian reserve function in women: A systematic review and meta-analysis
    7. Maternal and Neonatal Outcomes in Vedolizumab and Ustekinumab Exposed Pregnancies: Results from the PIANO registry
    8. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network
    9. European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation
    10. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer’s global safety database
    11. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry
    12. Risk Factors for Postpartum Disease Activity in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    13. Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
    14. Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease
    15. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis
    16. Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-Analysis
    17. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease
    18. The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    19. Biologics During Pregnancy in Women With IBD and Risk of Infantile Infections: A Systematic Review and Meta-Analysis
    20. The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    21. Preventive Health Care Among Postpartum Women With Inflammatory Bowel Disease: Results From the PIANO Registry
    22. Use of Biologic Therapy by Pregnant Women with Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines
    23. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group
    24. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report
    25. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development
    26. Safety of Flexible Sigmoidoscopy in Pregnant Patients with Known or Suspected Inflammatory Bowel Disease
    27. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease
    28. Inadequate Gestational Weight Gain Predicts Adverse Pregnancy Outcomes in Mothers with Inflammatory Bowel Disease: Results from a Prospective US Pregnancy Cohort
    29. Inadequate Gestational Weight Gain, the Hidden Link Between Maternal IBD and Adverse Pregnancy Outcomes: Results from the Norwegian Mother and Child Cohort Study
    30. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease
    31. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease
    32. Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    33. A meta-analysis on the influence of inflammatory bowel disease on pregnancy